Abstract:Importance: Differences in cerebrospinal fluid (CSF) tau Alzheimer dementia (AD) biomarkers by self-identified race have been observed in prior studies. More recently, plasma biomarkers have been gaining recognition, but whether they exhibit similar differences is unclear. Furthermore, the underlying explanation for these differences in AD biomarkers is still unexplored. Objectives: To investigate differences in plasma biomarkers by race and genetic ancestry and explore potential underlying explanations for these differences. Design, setting, and participants: This cross-sectional study used participant data from the Brain, Stress, Hypertension, and Aging Research Program (B-SHARP), an observational study conducted in the greater Atlanta metropolitan area. Participants were enrolled from March 1, 2016, to January 1, 2020. Main outcomes and measures: Main outcomes were plasma and CSF amyloid-β (Aβ) 42, Aβ40, phosphorylated tau181 (p-tau181), and neurofilament light. General linear models were used for key comparisons. Exposures: Main independent variables were self-identified race and genetic ancestry. Additional variables were cardiovascular factors, APOE4, educational attainment, Area Deprivation Index, and C-reactive protein (reflecting systemic inflammation state). Results: This analysis included 617 participants (mean [SD] age, 66 [7.9] years; 300 [49%] African American and 317 [51%] White; 429 [70%] with mild cognitive impairment). On the basis of self-reported race, plasma levels of Aβ42 (adjusted mean difference, -1.20 pg/mL; 95% CI, -2.33 to -0.07 pg/mL), Aβ40 (adjusted mean difference, -37.78 pg/mL; 95% CI, -60.16 to -15.39 pg/mL), p-tau181 (adjusted mean difference, -4.66 pg/mL; 95% CI, -7.05 to -1.90 pg/mL), and neurofilament light (adjusted mean difference, -1.58; 95% CI, -2.83 to -0.19 pg/mL) were consistently lower in African American individuals after adjusting for demographic characteristics, educational attainment, cognition, APOE4, and cardiovascular factors. A similar pattern was observed in the CSF biomarkers except for Aβ42 and Aβ40. Although unadjusted analyses revealed an association between these biomarkers and African ancestry, these associations were not significant after adjusting for the same covariates. Differences by self-reported race were not explained by varied cardiovascular risk factors, C-reactive protein, educational attainment, or Area Deprivation Index. Conclusions and relevance: In this cross-sectional study of plasma biomarkers by race and genetic ancestry, the results indicated that plasma p-tau181, Aβ40, and NFL were lower in African American individuals based on self-reported race but not genetic ancestry. These differences were not explained by cardiovascular risks or clinical stage differences. These racial differences should be considered in clinical interpretations and clinical trial screenings to avoid an additional increase in underrepresentation of African American individuals in AD trials.

Relationship Between Platelet Derived Growth Factor Receptor‐β and Alzheimer’s Biomarkers in a Racially Diverse, High‐risk Cohort

sPDGFRβ and neuroinflammation are associated with AD biomarkers and differ by race: The ASCEND Study

RACE MODIFIES THE RELATIONSHIP BETWEEN ALZHEIMER’S DISEASE (AD) BIOMARKERS AND COGNITION IN A COHORT OF MIDDLE-AGED INDIVIDUALS AT HIGH-RISK FOR AD

Baseline Results: the Association Between Cardiovascular Risk and Preclinical Alzheimer's Disease Pathology (ASCEND) Study.

Association of Plasma and Cerebrospinal Fluid Alzheimer Disease Biomarkers With Race and the Role of Genetic Ancestry, Vascular Comorbidities, and Neighborhood Factors

Association of Plasma Biomarkers of Alzheimer Disease With Cognition and Medical Comorbidities in a Biracial Cohort

Assessing blood-brain barrier dysfunction and its association with Alzheimer's pathology, cognitive impairment and neuroinflammation

Two Year Cognitive and Biomarker Change in a Racially Diverse, Middle‐aged, Cohort at Risk for Alzheimer’s Disease

Correlates of neuroimaging biomarkers in a middle‐age racially diverse cohort: Updates from the association between cardiovascular risk and preclinical Alzheimer’s Disease pathology (ASCEND) study

Changes in CSF Spdgfrβ Level and Their Association with Blood–brain Barrier Breakdown in Alzheimer’s Disease with or Without Small Cerebrovascular Lesions

Baseline levels and longitudinal rates of change in plasma Aβ42/40 among self-identified Black/African American and White individuals

Platelet-Derived Amyloid- Protein Precursor as a Biomarker of Alzheimer's Disease

Effect of Vascular Risk Factors on Blood-Brain Barrier and Cerebrospinal Fluid Biomarkers Along the Alzheimer's Disease Continuum: A Retrospective Observational Study

Baseline levels and longitudinal changes in plasma Aβ42/40 among Black and white individuals

Associations of CSF PDGFRβ With Aging, Blood-Brain Barrier Damage, Neuroinflammation, and Alzheimer Disease Pathologic Changes

Socioeconomic Status Mediates Racial Differences Seen Using the AT(N) Framework

PLASMA BIOMARKERS FOR ALZHEIMER’S DISEASE AND RELATED NEUROPATHOLOGY IN RELATION TO MCI AND DEMENTIA: THE ARIC STUDY

Blood-based Biomarkers for Alzheimer's Disease: a Multicenter-Based Cross-Sectional and Longitudinal Study in China.

Risk of Alzheimer's disease is associated with longitudinal changes in plasma biomarkers in the multi‐ethnic Washington Heights–Hamilton Heights–Inwood Columbia Aging Project (WHICAP) cohort

Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trial

Association of Plasma Amyloid-β and Dementia Among Black and White Older Adults